Profile | GDS2987 / GI_19882250-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 799 | 94 |
GSM215244 | HMVEC_vehicle_rep2 | 1126.7 | 95 |
GSM215253 | HMVEC_vehicle_rep3 | 1089.1 | 95 |
GSM215254 | HMVEC_atorvastatin_rep1 | 1517.2 | 96 |
GSM215282 | HMVEC_atorvastatin_rep3 | 1460 | 96 |
GSM215344 | HMVEC_atorvastatin_rep2 | 1526.2 | 96 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 1237.5 | 95 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 1164.5 | 95 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 1182.8 | 95 |
GSM215294 | HMVEC_SLx2119_rep1 | 750.9 | 94 |
GSM215295 | HMVEC_SLx2119_rep2 | 740.7 | 93 |
GSM215296 | HMVEC_SLx2119_rep3 | 619.4 | 91 |
GSM215297 | PASMC_vehicle_rep1 | 41.2 | 53 |
GSM215298 | PASMC_vehicle_rep2 | 3.9 | 7 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 24.8 | 40 |
GSM215312 | PASMC_atorvastatin_rep2 | 15.5 | 25 |
GSM215313 | PASMC_atorvastatin_rep3 | 49.5 | 58 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 24.3 | 39 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 19 | 35 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 3.4 | 6 |
GSM215327 | PASMC_SLx2119_rep1 | 3.7 | 7 |
GSM215328 | PASMC_SLx2119_rep2 | 17 | 31 |
GSM215329 | PASMC_SLx2119_rep3 | 10.7 | 21 |
GSM215330 | Fibroblasts_vehicle_rep1 | 0.6 | 2 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 15.8 | 41 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 20.6 | 45 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 2.8 | 10 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 6.8 | 19 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 0.7 | 2 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 1.4 | 4 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 9.4 | 24 |